AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00742911
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram.
Trial: NCT02985333
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 200mgmg/m(2) IV d1,3,5
Trial: NCT00884286
Drug: Aplidin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Trial: NCT01779921
Drug: Plasma-derived FVII conc. (pdFVII PFL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Trial: NCT00732069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
Trial: NCT01835938
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,
Trial: NCT02140281
Drug: Treatment A (cefadroxil alone)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
Trial: NCT02037633
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl IV
Trial: NCT01825928
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group,3mg/pill,3mg/day forced titration method,last 84 days
Trial: NCT02055781
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00194987
Drug: IVIG (Intravenous Immunoglobulin)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one gram per kg of IVIG per infusion given either once or twice
Trial: NCT00542243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given once a day for 6 months.
Trial: NCT03363971
Drug: Simulant agent for Zhi Kang Capsule
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
Trial: NCT01824082
Drug: Perineural infusion [continuous peripheral nerve block(s)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
Trial: NCT01616290
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03, 1, or 3 mg single adventitial administration
Trial: NCT01822028
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Trial: NCT01822028
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Trial: NCT00315445
Drug: Placebo oxycodone/acetaminophen tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Trial: NCT00315445
Drug: OXY/APAP
RxNorm normalized name: Acetaminophen/Propoxyphene Hydrochloride 650 MG-65 MG Oral Tablet [PROPOXY/APAP-65]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Trial: NCT00315445
Drug: Placebo transdermal patch (TDS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
Trial: NCT00684983
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03712098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
Trial: NCT00434005
Drug: N-acetylcysteine, ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
Trial: NCT00434005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched appearance to acetylcysteine and ascorbate intervention
Trial: NCT00959803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, oral single dose.
Trial: NCT00949442
Drug: human insulin [NPH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
Trial: NCT00959803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, oral twice daily for 7 days.
Trial: NCT04410523
Drug: CSJ117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment
Trial: NCT04410523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.
Trial: NCT03787927
Drug: Autologous Platelet Transfusion (room-temperature-stored)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Trial: NCT03787927
Drug: Autologous Platelet Transfusion (cold-stored 5 days)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Trial: NCT03787927
Drug: Autologous Platelet Transfusion (cold-stored 10 days)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Trial: NCT00359216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
Trial: NCT01505283
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural administration of 6 ml of NaCl 0.9%
Trial: NCT01505283
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epidural administration of sufentanil 10 µg
Trial: NCT00261105
Drug: telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01651364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
Trial: NCT00522873
Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Trial: NCT00522873
Drug: 0.5mg NETA / 1.0mg E2 (Activella)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Trial: NCT03381014
Drug: Chemotherapy, Cancer, Anthracyclines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
Trial: NCT00683449
Drug: Dose Group 1
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
Trial: NCT00683449
Drug: MN-221 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of placebo for 15 minutes
Trial: NCT00683449
Drug: Dose Group 2
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
Trial: NCT00683449
Drug: Dose Group 3
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
Trial: NCT03133468
Drug: AJM347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03133468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04643249
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03840915
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
Trial: NCT04643249
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or capsule
Trial: NCT02433093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 22 days of once-daily oral matching placebo capsules.
Trial: NCT03641976
Drug: Arm II (A-FOLFOX/A-FOLFIRI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV
Trial: NCT00948090
Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
Trial: NCT01376427
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT01819259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00822211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02873975
Drug: LY2606368
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02460016
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK0529 pellets for oral administration
Trial: NCT02582476
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
Trial: NCT00666601
Drug: TR-701 (pro-drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
Trial: NCT02114710
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Trial: NCT00157560
Drug: Chemotherapy, multiple agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02582476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
Trial: NCT00244179
Drug: dmard
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00484133
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03245281
Drug: Diuretic Suspension (DS)
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop diuretic consumption in the 48h before the follow-up visit
Trial: NCT00795366
Drug: Standard catecholamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
Trial: NCT03245281
Drug: Diuretic Increase (DI)
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double diuretics dosage in the 48h before the follow-up visit
Trial: NCT03245281
Drug: Diuretic and Medication Suspension (DMS)
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
Trial: NCT01749956
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00161655
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04603638
Drug: Isotonic
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml
Trial: NCT02441231
Drug: Visbiome
RxNorm normalized name: Visbiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visbiome probiotic
Trial: NCT03100877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01689597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00950586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match GSK1034702
Trial: NCT03150459
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for 12 weeks (Group 1)
Trial: NCT03150459
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day for 12 weeks (Group 2)
Trial: NCT01911416
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02344316
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken at 9 PM or 1 hour before bedtime, whichever is earlier
Trial: NCT03180177
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Trial: NCT02394769
Drug: Placebo for Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01120171
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity.
Trial: NCT02856854
Drug: Saline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine matched placebo
Trial: NCT01120171
Drug: Liposomal-encapsulated doxorubicin
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity.
Trial: NCT02139761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Trial: NCT00049140
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02271282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02271282
Drug: GHRH/Ghrelin combined Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
Trial: NCT03685604
Drug: PI Disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Trial: NCT00763360
Drug: Healon
RxNorm normalized name: Healon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
Trial: NCT00763360
Drug: Amvisc Plus
RxNorm normalized name: Amvisc Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
Trial: NCT03011996
Drug: CLR 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Trial: NCT03011996
Drug: AMX 1g
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Trial: NCT01171365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo inhaler two inhalations twice daily
Trial: NCT01010217
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Trial: NCT01840761
Drug: herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01840761
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00962663
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
Trial: NCT00913315
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once a day for 8 weeks
Trial: NCT02615080
Drug: CRD007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02615080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no